Jardiance
Named-patient access overview. Jardiance is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Jardiance (empagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor jointly developed by Boehringer Ingelheim and Eli Lilly. The US Food and Drug Administration first approved Jardiance in August 2014 for type 2 diabetes, with subsequent approvals for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease (2016), heart failure with reduced ejection fraction (2021), heart failure with preserved ejection fraction (2022), and chronic kidney disease (2023). It is dosed orally at 10 mg or 25 mg once daily.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Jardiance
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Jardiance is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Jardiance in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Jardiance
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.